Month: November 2022

Joffe & Associés (Christophe Joffe, Camille Malbezin and Rudy Diamant), in conjunction with Bennett Jones (Ian Michael, Jonathan Filippone), a Canadian law firm, is advising Adamson Systems Engineering on the acquisition of BeSpline and Brain Modular.

 

On Tuesday 15 November 2022, Olivier Sens, Sylvain Thevenard and Arnault Damien, the directors of the BeSpline and Brain Modular groups respectively, signed an agreement to transfer control of their companies to Adamson Systems Engineering. Based in Toronto, Canada, Adamson Systems Engineering is a company specialising in loudspeaker technologies for the professional audio sector.

 

For over 30 years, Adamson loudspeakers have been an essential part of global tours and festivals, and are installed in some of the world’s most prestigious venues. The companies BeSpline and BrainModular specialise in object-based sound spatialisation. BeSpline is notably the creator of the ‘Fletcher Machine’, which, through amplitude and time localisation, enables the listener to connect directly with the music.

 

This move will enable Adamson Systems Engineering to strengthen its presence in the professional audio sector through the integration of these innovative products, services and technological processes. Adamson Systems Engineering aims to expand its influence in the professional audio loudspeaker market and become a leading player in this field.

 

---

 

Partners: Christophe JOFFE, Rudy DIAMANT et Camille MALBEZIN.

FAUME is an online platform that enables brands to implement solutions and infrastructure related to the second-hand fashion market.

 

 

Launched in 2020, Faume is a company whose ambition is to enable brands to tap into the second-hand market by offering a combined technological and logistical solution. It is against this backdrop that the start-up Faume has raised €7 million from Daphni and its long-standing investor Bpifrance, via its Digital Venture fund, to help high-end brands offer a second-hand service. It is worth noting that the company had already raised €2 million in June 2021.

The Paris-based start-up provides brands with a customisable e-commerce site through which their customers can return products free of charge. According to the company’s four founders (Aymeric Déchin, Nicolas Viant, Jocelyn Kerbourc’h and Lucas Patricot), the widespread adoption of second-hand fashion will be driven by brands offering a service that meets customers’ expectations: the standards and quality of new goods.

 

The start-up already works with more than 30 European brands, including Isabel Marant, Aigle, SANDRO, Balzac Paris, HUGO BOSS, The Kooples, AMI PARIS, and now BA&SH, all of which have committed to this initiative alongside Faume. The values championed by FAUME are clear: circular, less polluting transactions, all without compromising on customers’ sense of fashion.

This fundraising round was led by FAUME’s Yellow fund, alongside Bpifrance Digital Venture and other major angel investors (Thibaud Hug de Larauze, Stanislas de Quercize, Michael Benabou, BERRY SERVICES, etc.).

 

“The customer experience is at the heart of our value proposition. Brands must indeed offer an experience that stands out from what is currently available, particularly in the face of platforms such as Vinted, Vestiaire Collective and LeBonCoin, which have made second-hand shopping mainstream,” explains Aymeric Déchin.

 

---

 

Partners: Thomas SALTIEL, Mathilde VASSEUR et Charlotte VIANDAZ.

Link to the CF News article: Medsenic article

 

In order to launch phase 3 of its clinical trial into the treatment of chronic graft-versus-host disease using arsenic salts, the Strasbourg-based company Medsenic is merging with the Belgian firm Bone Therapeutics, a specialist in orthopaedic cell therapy, on 25 October 2022. Medsenic is now conducting its trials of arsenic-based drugs across the border in Belgium.

 

 

The closing follows the fulfilment of all previous conditions precedent and the approval of the transaction at the Bone Therapeutics shareholders’ meeting (‘ESM’), which took place on Monday 24 October 2022.

The majority of Medsenic’s shareholders sold 51 per cent of the share capital in exchange for shares in Bone Therapeutics, at an estimated valuation of 40 million euros.

 

Renamed BioSenic upon completion of the transaction, the company is now led by Medsenic’s current chairman, François Rieger, who has been appointed CEO, supported by Véronique Pomi-Schneiter and Anne Leselbaum (Bone’s medical director). Jean-François Rax, the representative of Capital Grand Est, sits on the board of directors of Bone Therapeutics, which plans to acquire the remaining 49 per cent within thirty-six months.

This merger will enable the company to become the scientific hub of the new entity, expanding its therapeutic portfolio beyond its current trials.

 

“This agreement with Bone Therapeutics highlights the value of Medsenic’s highly complementary activities, offers our shareholders attractive and certain value, and brings together cutting-edge expertise and drug delivery platforms to accelerate growth and create new opportunities,” said François Rieger, Chairman and Chief Executive Officer of Medsenic.

 

---

Lead lewyers:

Christophe Joffe, Océane Christmann and François Galéa

 

Parties involved in the transaction:

Target company: MEDSENIC

Acquirer or investor: BIOSENIC(EX BONE THERAPEUTICS) , Jean Stéphenne

Seller: CAPITAL GRAND EST , FA DIESE , OUEST ANGELS CAPITAL , BUSINESS ANGEL(S)